A new publication about molecule property prediction: Molecule Attention Transformer

Topic:

Designing a molecule with desired properties is one of the biggest challenges in drug development. Read our latest article and learn about our solutions for augmenting compound design process.

Molecule Attention Transformer

 

Łukasz Maziarka, Tomasz Danel, Sławomir Mucha, Krzysztof Rataj, Jacek Tabor, Stanisław Jastrzebski

 

Designing a single neural network architecture that performs competitively across a range of molecule property prediction tasks remains largely an open challenge, and its solution may unlock a widespread use of deep learning in the drug discovery industry. To move towards this goal, we propose Molecule Attention Transformer (MAT). Our key innovation is to augment the attention mechanism in Transformer using inter-atomic distances and the molecular graph structure. Experiments show that MAT performs competitively on a diverse set of molecular prediction tasks. Most importantly, with a simple self-supervised pretraining, MAT requires tuning of only a few hyperparameter values to achieve state-of-the-art performance on downstream tasks. Finally, we show that attention weights learned by MAT are interpretable from the chemical point of view.

 

Download the full article here:

Molecule Attention Transformer

Expert Contribution

Reviewed by: Dr. Krzysztof Rataj, PhD
Role: Scientist, AI‑Driven Drug Discovery
Expertise: Bioinformatics, computational biology, ML‑driven drug discovery workflows, data analysis pipelines

You might be also interested in:

Poster: Bridging the Phenotype-Proteome Gap: A Multi-Modal AI Framework for analysis of Cell Painting images
Biomedical knowledge graph connecting drug discovery data, disease biology, targets and indications to support target prioritization and indication expansion
Knowledge Graphs in Drug Discovery: Bringing Context to Internal Data Assets
Molecular structure representing AI-supported antibody design for blood-brain barrier research
How BBB-Penetrating Antibodies Cross the Blood-Brain Barrier
Life sciences conference takeaways 2026 - AACR, PEGS Boston, SLAS Europe, and Bio-IT World summary on AI in drug discovery
What 4 Life Sciences Conferences Revealed About AI in Drug Discovery

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!